Viridian Therapeutics (VRDN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Viridian Therapeutics (VRDN) is Neutral.

The composite score behind that read is -0.10, weighing +0.01 of bullish evidence against -0.35 bearish.

Viridian Therapeutics last closed at $18.66, +1.74% on the session.

Against the IVW growth benchmark the position is +0.94% over the forecast window.

The read is built from 15 underlying insights — 2 bullish and 13 bearish.

Agreement across those insights is 87%.

8 graded predictions for VRDN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Viridian Therapeutics in the 13th percentile on return on equity, where 100 is best.

Viridian Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $2.08B.

StockMap tracks Viridian Therapeutics as the 86th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Viridian Therapeutics ranks 234th of 381 in the group, against a group median of -0.08.